Efficacy of Silodosin for Relieving Benign Prostatic Obstruction: Prospective Pressure Flow Study
|
|
- Arlene May
- 6 years ago
- Views:
Transcription
1 Efficacy of Silodosin for Relieving Benign Prostatic Obstruction: Prospective Pressure Flow Study Yoshihisa Matsukawa,* Momokazu Gotoh, Tomonori Komatsu, Yasuhito Funahashi, Naoto Sassa and Ryohei Hattori From the Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan Purpose: We investigated the effect of the new sympathetic 1A-adrenoceptor antagonist silodosin for relieving benign prostatic obstruction by pressure flow study. Materials and Methods: In this open, nonblinded, prospective study we administered 8 mg silodosin daily for 4 weeks in 60 patients with lower urinary tract symptoms associated with benign prostatic enlargement. As a primary outcome measure, we assessed changes in bladder function and benign prostatic obstruction using pressure flow study. As secondary outcome measures, changes in subjective symptoms and quality of life were assessed by the International Prostate Symptom Score. Objective changes in urination status were also assessed by free uroflowmetry in terms of maximum flow rate and post-void residual urine volume. Results: A total of 57 patients were enrolled for analysis. In the storage phase of the pressure flow study bladder capacity at first desire to void increased significantly with no significant change in maximum cystometric capacity. Of 24 patients 14 (58.3%) with uninhibited detrusor contractions before administration showed apparent improvement in detrusor overactivity after administration, including 6 in whom uninhibited contractions disappeared. In the voiding phase mean detrusor pressure at maximum flow significantly decreased from 72.5 to 51.4 cm H 2 O. The mean bladder outlet obstruction index decreased significantly from 60.6 to Obstruction grade assessed by the Schaefer nomogram improved in all except 1 patient. Total symptom and quality of life scores, maximum flow rate and post-void residual urine volume on free uroflowmetry significantly improved. Conclusions: Silodosin improved lower urinary tract symptoms by improving bladder storage function and relieving benign prostatic obstruction. Key Words: urinary bladder neck obstruction, prostatic hyperplasia, KMD 3213, adrenergic antagonists, urodynamics IN BPO cases various LUTS are caused by mechanical bladder outlet obstruction due to BPE or by functional obstruction due to increased tension of prostatic smooth muscle mediated by sympathetic nerves. 1 Changes in bladder function associated with BPO modify LUTS comprising voiding and storage symptoms. Because prostatic smooth muscle contraction is caused by sympathetic 1-AR stimulation, sympathetic 1-AR antagonists are widely used as first line drug therapy for LUTS associated with BPO. 2 4 Sympathetic 1-ARs, in- Abbreviations and Acronyms AR adrenoceptor BOOI bladder outlet obstruction index BPE benign prostatic enlargement BPH benign prostatic hyperplasia BPO benign prostatic obstruction I-PSS International Prostate Symptom Score LUTS lower urinary tract symptoms pdetqmax detrusor pressure at Qmax PFS pressure flow study PVR post-void residual urine Qmax maximum flow rate QOL quality of life Submitted for publication March 17, Study received Nagoya University Graduate School of Medicine ethics committee approval. * Correspondence: Department of Urology, Nagoya University Graduate School of Medicine, 65-Tsurumai-cho, Showa-ku, Nagoya , Japan (telephone: ; FAX: ; yoshi44@med.nagoya-u.ac.jp). For another article on a related topic see page /13/ /0 THE JOURNAL OF UROLOGY Vol. 189, S117-S121, January by AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH, INC. Printed in U.S.A. S117 Please cite this article as J Urol 2013;189: S117-S121. DOI:
2 S118 SILODOSIN FOR BENIGN PROSTATIC OBSTRUCTION cluding 1A, 1B and 1D-AR subtypes, have been identified with 1A and 1D-AR subtypes localized predominantly in the prostate, urethra and bladder neck, and 1B-AR subtype localized predominantly in blood vessels. 3,5 First-generation 1-AR antagonists such as prazosin and terazosin, which have no selectivity for sympathetic 1-AR subtypes, can cause adverse reactions related to vascular dilatation by inhibiting the 1B-AR subtype. Consequently in recent years second-generation 1-AR antagonists such as tamsulosin and naftopidil, which are selective for the 1A and 1D-AR subtypes, have come into wide use with the aim of decreasing adverse reactions. 6,7 Sympathetic 1-AR antagonists improve LUTS due to BPO, and provide relief of voiding and storage symptoms. 4,8 These drugs are thought to improve functional obstruction by relaxing prostatic smooth muscles, thereby relieving voiding symptoms. The mechanisms of storage symptom improvement are not clear. The beneficial effects of 1-AR antagonists on subjective symptoms have been investigated in detail based on quantitative symptomatic evaluation using questionnaires such as I-PSS. The objective effects of 1-AR antagonists on lower urinary tract function and particularly the beneficial effects on BPO require evaluation by urodynamic testing. PFS is particularly useful to objectively evaluate bladder contractile function and the degree of BPO. Although there have been few reports of the effects of 1-AR antagonists as measured by PFS, the beneficial effects of doxazosin, 9 tamsulosin 10 and alfuzosin 11 on BPO were reported based on PFS findings. Silodosin, which was recently developed as a new 1-AR antagonist, is purely selective for 1A-AR subtypes. This agent demonstrated affinity for the 1A-AR subtype that was 583-fold higher than for the 1B-AR subtype and 55.6-fold higher than for the 1D-AR subtype. 12 A phase III study of silodosin revealed its prominent beneficial effects on subjective symptoms and on the urinary flow rate on uroflowmetry. 13 This drug was launched in 2007 in Japan and in 2009 in the United States. To our knowledge there is no report of the objective effects of this drug on bladder function and BPO based on urodynamic testing. We investigated the effects of silodosin on bladder function and BPO using PFS in patients with LUTS due to BPE. PATIENTS AND METHODS The current investigation was an open, nonrandomized, single center prospective study. The protocol was approved by the ethics committee of Nagoya University Graduate School of Medicine, Nagoya, Japan. Study participants were patients with untreated BPE who visited our hospital from January 2007 to October 2008 complaining of LUTS. Study inclusion criteria were 1) I-PSS total score 8 points or greater, 2) I-PSS-QOL score 3 points or greater, 3) prostate volume 20 ml or greater on transperitoneal or transrectal ultrasonography, 4) urination Qmax greater than 100 ml but less than 15 ml per second on uroflowmetry, 5) PVR less than 100 ml and 6) patient age greater than 50 years. We excluded patients 1) on oral treatment with -antagonists, anticholinergic agents, antidepressants, anti-anxiety agents or antiandrogens, 2) suspected of having prostate cancer, 3) with neurogenic bladder dysfunction, bladder calculus or active urinary tract infection, 4) with serious cardiac complications, 5) with renal complications (serum creatinine 2 mg/dl or greater) and 6) with hepatic dysfunction (aspartate aminotransferase/alanine aminotransferase at least 2-fold higher than reference values). Silodosin as 4 mg capsules was administered orally twice daily for a total of 8 mg daily in 60 patients for 4 weeks. I-PSS and I-PSS-QOL scores, Qmax on free uroflowmetry and PVR were evaluated at baseline and 4 weeks after administration. PFS was performed before and after administration. For PFS bladder capacity at first desire to void, maximum cystometric capacity and the presence (pressure increase magnitude) or absence of uninhibited detrusor contractions in the storage phase were investigated along with Qmax, pdetqmax and PVR in the voiding phase. Apparent improvement in overactive bladder was defined as the disappearance of uninhibited detrusor contractions or a decrease in amplitude of uninhibited contractions of greater than 15 cm H 2 O. On PFS the degree of obstruction was assessed in terms of BOOI 14 according to International Continence Society recommendations before and after silodosin administration. Also, the obstruction grade of 0 to 6 based on the Schaefer nomogram was evaluated and baseline findings were compared with those after silodosin administration. Patients unable to continue oral administration due to adverse reactions and those who could not be evaluated after administration were excluded from analysis. Primary outcome measures were changes in bladder function and BPO on PFS. Secondary outcome measures were changes in subjective symptoms and QOL on I-PSS, and urination status on free uroflowmetry in terms of Qmax and PVR. PFS was performed by one of us (YM) based on standard International Continence Society methods. 15 A 6Fr single pigtail catheter was placed in the bladder transurethrally to measure intravesical pressure and an additional 8Fr catheter was inserted in the bladder to inject physiological (0.9%) saline solution. A balloon catheter was inserted from the anus to measure abdominal pressure. The test was done with the patient standing. Physiological saline solution was injected into the bladder at 50 ml per minute after evacuating the bladder. Intravesical pressure, abdominal pressure and detrusor pressure in the storage phase were simultaneously measured and recorded. After the patient expressed the maximum desire to urinate the catheter for injection was removed, leaving the 6Fr catheter to measure intravesical pressure, abdominal pressure, detrusor pressure and urinary flow in the voiding phase, which were recorded simultaneously. Statistical analysis was done with the paired or nonpaired
3 SILODOSIN FOR BENIGN PROSTATIC OBSTRUCTION S119 Student t and Wilcoxon rank tests with p 0.05 considered significant. Values at baseline and 4 weeks after silodosin administration Mean SD Baseline Mean SD 4 Wks p Value I-PSS I-PSS-QOL Uroflowmetry: Qmax (ml/sec) Voided vol (ml) PVR (ml) Bladder capacity at first void desire (ml) Max cystometric capacity (ml) pdetqmax (cm H 2 O) Qmax (ml/sec) PVR (ml) BOOI RESULTS Two patients could not continue administration due to adverse reactions and 1 was unable to undergo PFS after administration. The 57 patients who completed the investigation were 51 to 84 years old (mean age 68.5) with a prostate volume of 25 to 120 ml (mean 42.0). Total I-PSS and I-PSS-QOL scores were significantly improved after drug administration. On free uroflowmetry Qmax and PVR were significantly improved without a significant change in voided volume (see table). The table shows changes in parameters measured by PFS from baseline to after administration. Bladder volume at first desire to void significantly increased but maximum cystometric capacity showed no significant change. Uninhibited detrusor contraction was observed in 24 patients (42.1%) before silodosin administration. After drug administration 14 of the 24 patients (58.3%) had apparent improvement in detrusor overactivity and in 6 (25%) uninhibited detrusor contraction disappeared. In 8 patients (33.3%) in whom uninhibited detrusor contraction amplitude showed a remarkable decrease of greater than 15 cm H 2 O the mean amplitude of uninhibited detrusor contraction decreased from 51.6 to 11.5 cm H 2 O. None of the 33 patients who were free from uninhibited detrusor contraction before administration showed uninhibited contraction upon testing after administration. Qmax and PVR significantly improved after silodosin administration, similar to findings on free uroflowmetry. After administration pdetqmax significantly decreased from 72.5 to 51.4 cm H 2 O for a mean decrease of 21.1 cm H 2 O. BOOI decreased in all patients and mean BOOI significantly decreased from 60.6 to 33.8 after administration (p ). As evaluated by the Schaefer nomogram, the degree of obstruction improved by 3 levels in 8 patients, by 2 in 20 and by 1 in 28, and was unchanged in only 1. DISCUSSION Investigation of the ratio of mrna expression to 1-AR subtypes in human prostate tissue showed that 1A-AR up-regulation occurs in patients with BPH, in whom mrna expression of the 1A-AR subtype is about 9-fold higher than in normal individuals. 16 Therefore, 1A-ARs are considered important factors in functional bladder outlet obstruction in BPH cases. Based on such findings second-generation 1-AR antagonists such as tamsulosin, which act selectively on 1A-ARs, have come into broad use as first line drug treatment for this condition worldwide. 2,6,7 Silodosin is a new, unique 1-AR antagonist that is purely selective for 1A-ARs. In a randomized comparative study of silodosin vs tamsulosin and placebo the superiority of silodosin vs placebo and the noninferiority of this drug vs tamsulosin were demonstrated by I-PSS and I-PSS-QOL scores, and Qmax on free uroflowmetry. 13 In regard to subjective symptoms silodosin significantly improves not only I-PSS total score but also voiding and storage symptom scores. 13,17 The beneficial effects of silodosin on subjective symptoms and on Qmax on uroflowmetry were similarly confirmed in our study. Although uroflowmetry reflects voiding function, uroflowmetry parameters are determined by urethral resistance and bladder contractile force, making it difficult to evaluate the degree of lower urinary tract obstruction only by uroflowmetry parameters. PFS is the only method that can accurately evaluate the presence and extent of BPO. Because to our knowledge there have been no reports of the effects of silodosin as measured by PFS, we used PFS to objectively evaluate the beneficial effects of silodosin on BPO. Our results showed significant improvements in parameters related to voiding function on PFS after silodosin administration. This drug improved subjective symptoms in patients with BPH with LUTS and provided beneficial effects on voiding function by decreasing BPO. Mean BOOI before administration was as high as 60.6, suggesting apparent obstruction, but it significantly decreased to 30.8 after administration. When we evaluated findings using the Schaefer nomogram, the degree of obstruction improved in all except 1 patient. A few groups have used PFS to assess the effects of 1-AR antagonists. In randomized, controlled studies comparing 1-AR antagonists and placebo the decrease in pdetqmax was significantly greater after administering alfuzo-
4 S120 SILODOSIN FOR BENIGN PROSTATIC OBSTRUCTION sin 9 or doxazosin 11 than after placebo, and tamsulosin showed a remarkable decrease in pdetqmax compared with that in the placebo group, although this decrease was not significant. 10 Tatemichi et al reported the suppressive effects of silodosin on detrusor overactivity in rats 18 but to our knowledge such effects have not been reported in humans. The increase in bladder capacity at first desire to void and the suppression of uninhibited detrusor contraction observed on PFS in our study objectively suggest that this drug beneficially affects storage function. Improvement in storage symptoms is associated with terazosin 19 (not selective for 1-AR subtypes), tamsulosin 6 (selective for 1A 1D 1B-ARs) and naftopidil 20 (selective for 1D 1A 1B-ARs). These findings clearly suggest that 1-AR antagonists improve not only voiding symptoms but also storage symptoms regardless of selectivity for 1-AR subtypes. The mechanisms of the beneficial effects of 1-AR antagonists on storage function are not well characterized and several hypotheses have been proposed. Up-regulation of 1D-ARs occurs in the obstructed rat bladder 21 and 1D-ARs are localized predominantly in the human bladder. 5 This suggests that the involvement of bladder 1D-ARs in storage symptoms and the beneficial effects of 1-AR antagonists on storage function occur via 1D-ARs. Several experimental series support the role of 1D-ARs in regulating bladder storage function. 7,22 25 This hypothesis is negated by the observations that 1-AR expression is extremely sparse in human bladder smooth muscle and 3-ARs account for 96% of sympathetic receptors. 26 Also, a randomized clinical study comparing tamsulosin and naftopidil revealed no difference between these 2 drugs in regard to improvement in storage symptoms. 7 Our results indicate that the 1A-AR subtype is also associated with storage symptoms but to our knowledge mechanisms to improve bladder storage function by suppressing 1A-ARs remain unknown. Mechanical stimulation of urethral afferent nerves causes bladder contraction and uninhibited detrusor contractions have been suppressed by mucosal anesthesia of the prostatic urethra with lidocaine in patients with BPH. 27 Relaxing the prostate gland and urethral smooth muscle by 1A-AR antagonists may suppress afferent stimulation and improve storage symptoms. The role of 1A-ARs in terms of the storage function is poorly understood and is an interesting area for future investigation. Our series has some limitations. Since this study was open and nonblinded, several factors are open to bias. Observer bias when analyzing PFS would be possible but we believe that this would not have caused a serious impact on the study outcome since at least 2 of us read the PFS tracing and assessed the data. Another limitation is a leaning bias in patients when urodynamics were repeated in the same patients. The change in pdetqmax and obstruction grade were highly significant in our series but in previous randomized, controlled studies comparing other 1-AR antagonists and placebo pdetqmax decreases were observed to a certain degree, although they were not significant. 9,10,11 CONCLUSIONS Silodosin is a novel 1-AR antagonist that is purely selective for 1A-AR subtypes. It improved voiding and storage symptoms in patients with BPH. Objective findings based on PFS storage and voiding phases show that this agent improves bladder storage function and BPO. REFERENCES 1. Shapiro E, Becich MJ, Hartanto V et al: The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. J Urol 1992; 147: American Urological Association guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 2003; 170: Schwinn DA and Roehrborn CG: Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol 2008; 15: Andersson KF: Alpha-adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoceptor antagonists. World J Urol 2002; 19: Malloy BJ, Price DT, Price RR et al: Alpha1- adrenergic receptor subtypes in human detrusor. J Urol 1998; 160: Lepor H: Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic. hyperplasia. Urology 1998; 51: Gotoh M, Kamihira O, Kinukawa T et al: Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. BJU Int 2005; 96: Cooper KL, McKiernan JM and Kaplan SA: Alphaadrenoceptor antagonists in the treatment of benign prostatic hyperplasia. Drugs 1999; 57: Martorana G, Giberti C, Di Silverio F et al: Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia. Eur Urol 1997; 32: Abrams P, Speakman M, Stott M et al: A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia). Br J Urol 1997; 80: Ozbey I, Aksoy Y, Polat O et al: Effects of doxazosin in men with benign prostatic hyperplasia: urodynamic assessment. Int Urol Nephrol 1999; 31: Shibata K, Foglar R, Horie K et al: KMD-3213, a novel, potent, 1A adrenoceptor-selective antagonist: characterization using recombinant
5 SILODOSIN FOR BENIGN PROSTATIC OBSTRUCTION S121 human 1-adrenoceptors and native tissues. Mol Pharmacol 1995; 48: Kawabe K, Yoshida M and Homma Y: Silodosin, a new alpha1a-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 2006; 98: Abrams P: Bladder outlet obstruction index, bladder contractility index and bladder voiding efficacy: three simple indices to define bladder voiding function. BJU Int 1999; 84: Abrams P, Cardozo L, Fall M et al: The standardisation of terminology in lower urinary tract function: report from the Standardisation Subcommittee of the International Continence Society. Urology 2003; 61: Nasu K, Moriyama N, Fukasawa R et al: Quantification and distribution of alpha1-adrenoceptor subtype mrnas in human proximal urethra. Br J Pharmacol 1998; 123: Takao T, Tsujimura A, Kiuchi H et al: Early efficacy of silodosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Int J Urol 2008; 15: Tatemichi S, Akiyama K, Kobayashi M et al: A selective alpha1a-adrenoceptor antagonist inhibits detrusor overactivity in a rat model of benign prostatic hyperplasia. J Urol 2006; 176: Elhilali MM, Ramsey EW, Barkin J et al: A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. Urology 1996; 47: Yamanishi T, Yasuda K, Kamai T et al: Singleblind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia. Int J Urol 2004; 11: Hampel C, Dolber PC, Smith MP et al: Modulation of bladder 1 adrenergic receptor subtype expression by bladder outlet obstruction. J Urol 2002; 167: Smith MS, Schambra UB, Wilson KH et al: Alpha 1-adrenergic receptors in human spinal cord: specific localized expression of mrna encoding alpha 1-adrenergic subtypes at four distinct levels. Brain Res Mol Brain Res 1999; 63: Persson K, Pandita RK, Spitsbergen JM et al: Spinal and peripheral mechanisms contributing to hyperactive voiding in spontaneously hypertensive rats. Am J Physiol 1998; 275: Chen Q, Takahashi S, Zhong S et al: Function of the lower urinary tract in mice lacking alpha 1d-adrenoceptor. J Urol 2005; 174: Ishihama H, Momota Y, Yanase H et al: Activation of alpha 1D adrenergic receptors in the rat urothelium facilitates the micturition reflex. J Urol 2006; 175: Nomiya M and Yamaguchi O: A quantitative analysis of mrna expression of alpha 1 and betaadrenergic subtypes and their functional roles in human normal and obstructed bladders. J Urol 2003; 170: Yokoyama O, Nagano K, Kawaguchi K et al: The influence of prostatic urethral anesthesia in overactive detrusor in patients with benign prostatic hyperplasia. J Urol 1994; 151: 1554.
New Treatment Modalities for Benign Prostatic Hyperplasia. Seung-June Oh, MD Department of Urology, Seoul National University Hospital
New Treatment Modalities for Benign Prostatic Hyperplasia Seung-June Oh, MD Department of Urology, Seoul National University Hospital Options for Treating BPH Pharmacotherapy blocker Agents for BPH + OAB
More informationFerdinando Fusco * , Massimiliano Creta, Nicola Longo, Francesco Persico, Marco Franco and Vincenzo Mirone
Fusco et al. BMC Urology (2018) 18:12 https://doi.org/10.1186/s12894-018-0326-7 RESEARCH ARTICLE Open Access Silodosin 8 mg improves benign prostatic obstruction in Caucasian patients with lower urinary
More informationAlpha antagonists from initial concept to routine clinical practice
european urology 50 (2006) 635 642 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Alpha antagonists from initial concept to routine clinical practice
More informationSilodosin versus naftopidil for the treatment of benign prostatic hyperplasia: A multicenter randomized trial
The study protocol was approved by the ethics committee and institutional review board of Nihon University School of Medicine. Written informed consent was obtained from all patients. From December 2007
More informationNaoki Wada, Seiji Matsumoto, Masafumi Kita, Kazumi Hashizume and Hidehiro Kakizaki
bs_bs_banner International Journal of Urology (1) 1, 15 1 doi: 1.1111/iju.157 Original Article: Clinical Investigation Decreased urinary nerve growth factor reflects prostatic volume reduction and relief
More informationOriginal Article. Introduction. Methods. Abstract
Blackwell Science, LtdOxford, UKIJUInternational Journal of Urology0919-81722003 Blackwell Publishing Asia Pty LtdNovember 20031011587594Original ArticleUsefulness of a1-blockers in BPHI Ikemoto et al.
More informationORIGINAL ARTICLE. Key words benign prostatic hyperplasia, bother, lower urinary tract symptoms, quality of life, tamsulosin
LUTS (2012) 4, 45 50 ORIGINAL ARTICLE Correlations among Lower Urinary Tract Symptoms, Bother, and Quality of Life in Patients with Benign Prostatic Hyperplasia and Associated Fluctuations with Tamsulosin
More informationSilodosin From Bench to Bedside: Selectivity, Safety, and Sustained Efficacy
EUROPEAN UROLOGY SUPPLEMENTS 10 (2011) 445 450 available at www.sciencedirect.com journal homepage: www.europeanurology.com Silodosin From Bench to Bedside: Selectivity, Safety, and Sustained Efficacy
More informationRole of silodosin in patients with LUTS/BPE non responding to medical treatment with tamsulosin: a prospective, open-label, pilot study
European Review for Medical and Pharmacological Sciences 2017; 21: 4941-4945 Role of silodosin in patients with LUTS/BPE non responding to medical treatment with tamsulosin: a prospective, open-label,
More informationOriginal Article - Voiding Dysfunction
www.kjurology.org http://dx.doi.org/10.4111/kju.2014.55.5.335 Original Article - Voiding Dysfunction http://crossmark.crossref.org/dialog/?doi=10.4111/kju.2014.55.5.335&domain=pdf&date_stamp=2014-05-16
More informationMale lower urinary tract symptoms and α 1D -adrenoceptors. and Karl-Erik Andersson 2. Winston Salem, NC, USA
Male lower urinary tract symptoms and α 1D -adrenoceptors Osamu Ishizuka, 1 Tetsuya Imamura, 1 Yoshiki Kurizaki, 1 Osamu Nishizawa 1 and Karl-Erik Andersson 2 1 Department of Urology, Shinshu University
More informationTHE EVOLUTION OF DETRUSOR OVERACTIVITY AFTER WATCHFUL WAITING, MEDICAL THERAPY AND SURGERY IN PATIENTS WITH BLADDER OUTLET OBSTRUCTION
0022-5347/03/1692-0535/0 Vol. 169, 535 539, February 2003 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2003 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000045600.69261.73 THE EVOLUTION
More informationDiagnostic approach to LUTS in men. Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center
Diagnostic approach to LUTS in men Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center Classification of LUTS Storage symptoms Voiding symptoms Post micturition
More informationCHAPTER 6. M.D. Eckhardt, G.E.P.M. van Venrooij, T.A. Boon. hoofdstuk :49 Pagina 89
hoofdstuk 06 19-12-2001 09:49 Pagina 89 Urethral Resistance Factor (URA) Versus Schäfer s Obstruction Grade and Abrams-Griffiths (AG) Number in the Diagnosis of Obstructive Benign Prostatic Hyperplasia
More informationOffice Management of Benign Prostatic Enlargement
Focus on CME at McGill University Office Management of Benign Prostatic Enlargement Symptomatic benign prostate enlargement is a common medical problem encountered in our aging society. Watchful waiting,
More informationOriginal Research Article
International Surgery Journal Singh SN et al. Int Surg J. 218 May;():1866-1872 http://www.ijsurgery.com pissn 2349-33 eissn 2349-292 Original Research Article DOI: http://dx.doi.org/1.1823/2349-292.isj218199
More informationInvestigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasia
Sakata and Morita BMC Urology 2012, 12:29 RESEARCH ARTICLE Open Access Investigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasia Koichi Sakata 1* and Tatsuo Morita 2
More informationThe Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (6), Page
The Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (6), Page 1377-1386 Evaluation of Silodosin in Comparison to Tamuslosin in Treatment of Benign Prostatic Hyperplasia with lower Urinary
More informationOriginal Article. J Fac Med Baghdad 119. Nibbras I. AL-Hamdani* Ali W. Zeki*** Introduction:
Original Article The Efficacy of Solifenacin Added to Α-Adrenergic Antagonists in the Treatment of Lower Urinary Tract Symptoms in Males with Benign Prostate Hyperplasia (The Iraqi Experience) Nibbras
More informationCorrespondence should be addressed to Yoshinori Tanaka;
Hindawi Advances in Urology Volume 2017, Article ID 4842025, 6 pages https://doi.org/10.1155/2017/4842025 Clinical Study The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment
More informationManagement of LUTS after TURP and MIT
Management of LUTS after TURP and MIT Hong Sup Kim Konkuk University TURP & MIT TURP : Gold standard MIT TUIP TUNA TUMT HIFU LASER Nd:YAG, ILC, HoLRP, KTP LUTS after TURP and MIT Improved : about 70% Persistent
More informationRole of herbal drugs in the management of benign prostatic hyperplasia: Clinical trial to evaluate the efficacy and safety of Himplasia
[Medicine Update (2003): 11(2), 55-58] Role of herbal drugs in the management of benign prostatic hyperplasia: Clinical trial to evaluate the efficacy and safety of Himplasia Arora, R.P., CMO, Rajiba L.
More informationLONG-TERM SAFETY AND EFFICACY OF TAMSULOSIN FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA
0022-5347/03/1702-0498/0 Vol. 170, 498 502, August 2003 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2003 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000076140.68657.fd LONG-TERM SAFETY
More informationOriginal Article INTRODUCTION. Abstract
Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijss/2017/02 Comparison of Silodosin with Tamsulosin in Patients with Symptomatic Benign Prostatic Hyperplasia: A Prospective,
More informationA Comparative Study of Efficacy and Safety Between Tamsulosin and Terazosin in the Treatment of Symptomatic Benign Prostatic Hyperplasia
Chattagram Maa-O-Shishu Hospital Medical College Journal Original Article A Comparative Study of Efficacy and Safety Between Tamsulosin and Terazosin in the Treatment of Symptomatic Benign Prostatic Hyperplasia
More informationL ower urinary tract symptoms (LUTS) are a major health problem and are prevalent in men aged.45 years1 3.
OPEN SUBJECT AREAS: UROGENITAL DISEASES DRUG DEVELOPMENT Received 23 October 2013 Accepted 15 January 2014 Published 4 February 2014 Correspondence and requests for materials should be addressed to P.H.
More informationα 1 adrenergic receptor antagonists versus placebo for female lower urinary tract symptoms: A meta analysis
EXPERIMENTAL AND THERAPEUTIC MEDICINE 10: 251-256, 2015 α 1 adrenergic receptor antagonists versus placebo for female lower urinary tract symptoms: A meta analysis PENG ZHANG 1, WAN LI HU 1, BEI CHENG
More informationThe Journal of International Medical Research 2012; 40:
The Journal of International Medical Research 2012; 40: 899 908 Comparison of α-blocker Monotherapy and α-blocker Plus 5α-Reductase Inhibitor Combination Therapy Based on Prostate Volume for Treatment
More informationPredictors of short-term overactive bladder symptom improvement after transurethral resection of prostate in men with benign prostatic obstruction
bs_bs_banner International Journal of Urology (2014) 21, 1035 1040 doi: 10.1111/iju.12482 Original Article: Clinical Investigation Predictors of short-term overactive bladder symptom improvement after
More informationClinical Study Treatment Strategy According to Findings on Pressure-Flow Study for Women with Decreased Urinary Flow Rate
Advances in Urology Volume 2009, Article ID 782985, 5 pages doi:10.1155/2009/782985 Clinical Study Treatment Strategy According to Findings on Pressure-Flow Study for Women with Decreased Urinary Flow
More informationClinically and Statistically Significant Changes Seen in Sham Surgery Arms of Randomized, Controlled Benign Prostatic Hyperplasia Surgery Trials
Clinically and Statistically Significant Changes Seen in Sham Surgery Arms of Randomized, Controlled Benign Prostatic Hyperplasia Surgery Trials Charles Welliver,*, Michael Kottwitz, Paul Feustel and Kevin
More informationTHE ACONTRACTILE BLADDER - FACT OR FICTION?
THE ACONTRACTILE BLADDER - FACT OR FICTION? Jacob Golomb Department of Urology Chaim Sheba Medical Center Tel Hashomer NEUROGENIC UNDERACTIVE DETRUSOR Central (complete/incomplete): Spinal cord injury-
More informationAdrenoceptor Antagonist Tamsulosin for the Treatment of Voiding Symptoms Improves Nocturia and Sleep Quality in Women. The α 1 FEMALE UROLOGY
The α 1 Adrenoceptor Antagonist Tamsulosin for the Treatment of Voiding Symptoms Improves Nocturia and Sleep Quality in Women Sun-Ouck Kim, Hyang Sik Choi, Dongdeuk Kwon FEMALE UROLOGY Department of Urology,
More informationCombination Drug Therapy for Benign Prostatic Hyperplasia (BPH)
The Annals of African Surgery www.sskenya.org Combination Drug Therapy for Benign Prostatic Hyperplasia (BPH) Author: Oliech J.S. FRCS, Affiliation: Department of Surgery, University of Nairobi. P.O. Box
More informationKey words: Lower Urinary Tract Symptoms (LUTS), Prostatic Hyperplasia, Alpha-1 Adrenoceptor Antagonists, Tamsulosin, Terazosin.
The Professional Medical Journal DOI: 10.17957/TPMJ/17.4102 ORIGINAL PROF-4102 PROSTATIC HYPERPLASIA; COMPARISON BETWEEN TAMSULOSIN AND TERAZOSIN FOR EFFICACY IN MEDICAL MANAGEMENT OF LOWER URINARY TRACT
More informationNovel Natural Fill Telemetric Pressure Flow Study of Discomfort and Bladder Outlet Obstruction
Novel Natural Fill Telemetric Pressure Flow Study of Discomfort and Bladder Outlet Obstruction Hyoun-Joong Kong, Sunmee Park, Tack Lee, Ji Youl Lee, Hee Chan Kim and Seung-June Oh* From the Interdisciplinary
More informationAbstract. Key words Trial without catheter, Acute urinary retention, Benign prostatic hyperplasia, Introduction
The role of sustained-released alfuzosin in the treatment of acute urinary retention Mohamed Fawzi Ahmed. Department of Surgery, Ninevah College of Medicine, University of Mosul. Abstract To see whether
More informationIncreasing Awareness, Diagnosis, and Treatment of BPH, LUTS, and EP
Introduction to Enlarged Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David Crawford Endowed Chair in Urologic Oncology University of
More informationEffect of Transurethral Resection of the Prostate Based on the Degree of Obstruction Seen in Urodynamic Study
www.kjurology.org http://dx.doi.org/10.4111/kju.2013.54.12.840 Voiding Dysfunction/Female Urology Effect of Transurethral Resection of the Prostate Based on the Degree of Obstruction Seen in Urodynamic
More informationThe Evolution of Combination Therapy. US men eligible for BPH treatment * with projected population changes
The Management of BPH & The Impact of Combination Therapy Results Combination of Avodart and Tamsulosin (CombAT) Medical Therapy of Prostate Symptoms (MTOPS) Dr. Jack Barkin, md, fics, facs, dabu, Mcert
More informationEXPERIMENTAL AND THERAPEUTIC MEDICINE 4: , 2012
1112 Usefulness of total bladder capacity and post void residual urine volume as a predictor of detrusor overactivity with impaired contractility in stroke patients SANG HYUB LEE, JOONG GEUN LEE, GYEONG
More informationLasers in Urology. Sae Woong Choi, Yong Sun Choi, Woong Jin Bae, Su Jin Kim, Hyuk Jin Cho, Sung Hoo Hong, Ji Youl Lee, Tae Kon Hwang, Sae Woong Kim
www.kjurology.org http://dx.doi.org/10.4111/kju.2011.52.12.824 Lasers in Urology 120 W Greenlight HPS Laser Photoselective Vaporization of the Prostate for Treatment of Benign Prostatic Hyperplasia in
More informationSummary. Neuro-urodynamics. The bladder cycle. and voiding. 14/12/2015. Neural control of the LUT Initial assessment Urodynamics
Neuro-urodynamics Summary Neural control of the LUT Initial assessment Urodynamics Marcus Drake, Bristol Urological Institute SAFETY FIRST; renal failure, dysreflexia, latex allergy SYMPTOMS SECOND; storage,
More informationUrethral Sensations are Related to the Development of Detrusor Overactivity
LUTS (2011) 3, 59 63 REVIEW ARTICLE Urethral Sensations are Related to the Development of Detrusor Overactivity Osamu YOKOYAMA, Yoshiji MIWA, Nobuyuki OYAMA, Yoshitaka AOKI, Hideaki ITO, Kazuya TANASE,
More informationImpact of urethral catheterization on uroflow during pressure-flow study
Research Report Impact of urethral catheterization on uroflow during pressure-flow study Journal of International Medical Research 2016, Vol. 44(5) 1034 1039! The Author(s) 2016 Reprints and permissions:
More informationThe Journal of International Medical Research 2005; 33:
The Journal of International Medical Research 2005; 33: 562 573 A Comparative Study on the Safety and Efficacy of Tamsulosin and Alfuzosin in the Management of Symptomatic Benign Prostatic Hyperplasia:
More informationIndex. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Ablative therapies, transurethral needle ablation, Adverse events, sexual side effects of BPH Aging, and incidence of BPH associated with
More informationWho Would Benefit from Solifenacin Add-On Therapy to Tamsulosin for Overactive Bladder Symptoms Associated with Benign Prostatic Hyperplasia?
LUTS (2013) 5, 145 149 ORIGINAL ARTICLE Who Would Benefit from Solifenacin Add-On Therapy to Tamsulosin for Overactive Bladder Symptoms Associated with Benign rostatic Hyperplasia? Jun OBATA, Kazuhiro
More informationWhat should we consider before surgery? BPH with bladder dysfunction. Inje University Sanggye Paik Hospital Sung Luck Hee
What should we consider before surgery? BPH with bladder dysfunction Inje University Sanggye Paik Hospital Sung Luck Hee Diagnostic tests in three categories Recommendation: there is evidence to support
More informationProfile of Silodosin. Francesco Montorsi * Article info. Abstract
EUROPEAN UROLOGY SUPPLEMENTS 9 (2010) 491 495 available at www.sciencedirect.com journal homepage: www.europeanurology.com Profile of Silodosin Francesco Montorsi * Department of Urology, University Vita-Salute
More informationUrodynamic Assessments of Bladder Outflow Obstruction Associated with Benign Prostatic Hyperplasia
Original Article Urodynamic Assessments of Bladder Outflow Obstruction Associated with Benign Prostatic Hyperplasia Kun Dou, MD; QiGui Liu, MD; Xin Li, MD; QingYu Zhou, MD; XiaoLu Han, MD Kun Dou is a
More informationProstate Health PHARMACIST VIEW
Prostate Health PHARMACIST VIEW Prostate Definition Prostate is a gland made of fibromuscular tissue. It is about 4 cm and surrounds the neck of the bladder and the urethra. It produces seminal fluid.
More informationOriginal Article Japanese Urological Association. International Journal of Urology (2006) 13,
Blackwell Publishing AsiaMelbourne, AustraliaIJUInternational Journal of Urology0919-81722006 Blackwell Publishing Asia Pty Ltd2006130014051409Original ArticleTamsulosin vs doxazosin in BPH D Rahardjo
More informationEjaculation. Emission. Ejection. Orgasm
Ejaculation Emission Ejection Orgasm Ejaculation sc T10-L2 S2-4 Emission: vas deferens, prostate, bladder neck Post. Urethra distention Ejection: Pelvic Floor / bulbocavernous muscle contraction Orgasm:
More informationLower Urinary Tract Symptoms (LUTS) and Nurse-Led Clinics. Sean Diver Urology Advanced Nurse Practitioner candidate Letterkenny University Hospital
Lower Urinary Tract Symptoms (LUTS) and Nurse-Led Clinics Sean Diver Urology Advanced Nurse Practitioner candidate Letterkenny University Hospital 01/02/2018 Lower Urinary Tract Symptoms LUTS - one of
More informationNeurogenic bladder. Neurogenic bladder is a type of dysfunction of the bladder due to neurological disorder.
Definition: Neurogenic bladder Neurogenic bladder is a type of dysfunction of the bladder due to neurological disorder. Types: Nervous system diseases: Congenital: like myelodysplasia like meningocele.
More informationDiagnosis and Mangement of Nocturia in Adults
Diagnosis and Mangement of Nocturia in Adults Christopher Chapple Professor of Urology Sheffield Teaching Hospitals University of Sheffield Sheffield Hallam University UK 23 rd October 2015 Terminology
More informationVoiding Dysfunction Block lecture, 5 th year student. Choosak Pripatnanont, Department of Surgery, PSU.
Voiding Dysfunction 2009 Block lecture, 5 th year student. Choosak Pripatnanont, Department of Surgery, PSU. Objectives Understand and explain physiologic function and dysfunction of lower urinary tract.
More informationElderly Men with Luts: The Role of Urodynamics
Original Research Paper Medical Science Elderly Men with Luts: The Role of Urodynamics Dr. Ala a Al-Deen Al-Dabbagh Consultant urologist,al-yarmouk Teaching Hospital Department of urology/baghdad/iraq,
More informationImpact of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Treatment with Tamsulosin and Solifenacin Combination Therapy on Erectile Function
www.kjurology.org DOI:10.4111/kju.2011.52.1.49 Sexual Dysfunction Impact of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Treatment with Tamsulosin and Solifenacin Combination Therapy on Erectile
More informationIndex. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Ablation, of prostate, holmium laser, 485 495 African prune tree (Pygeum africanum), 454 455 Alfuzosin, 445 446 Alpha-adrenergic agonists,
More informationMMM. Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS
Dr Tan & Partners MMM Vol. 1 No. 1 Morbidity & Mortality Meeting 14 th November 2014 Introduction Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS Tadalafil 5mg daily is a well established
More informationBenign Prostatic Hyperplasia. Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary
Benign Prostatic Hyperplasia Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied,
More informationThe Pharmacological Profile of the a 1A -Adrenoceptor Antagonist Silodosin
EUROPEAN UROLOGY SUPPLEMENTS 9 (2010) 486 490 available at www.sciencedirect.com journal homepage: www.europeanurology.com The Pharmacological Profile of the a 1A -Adrenoceptor Antagonist Silodosin Martin
More informationCan 80 W KTP Laser Vaporization Effectively Relieve the Obstruction in Benign Prostatic Hyperplasia?: A Nonrandomized Trial
pissn: 2287-428 / eissn: 2287-469 World J Mens Health 212 December 3(3): 16-165 http://dx.doi.org/1.5534/wjmh.212.3.3.16 Original Article Can 8 W KTP Laser Vaporization Effectively Relieve the Obstruction
More informationTamsulosin sustained release preparation in patients of lower urinary tract symptoms due to benign prostatic hyperplasia
J. Acad. Indus. Res. Vol. 1(11) April 2013 679 RESEARCH MANUSCRIPT ISSN: 2278-5213 Tamsulosin sustained release preparation in patients of lower urinary tract symptoms due to benign prostatic hyperplasia
More informationMANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH
MANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH INTRODUCTION (1) Part of male sexual reproductive organ Size
More informationChapter 4: Research and Future Directions
Chapter 4: Research and Future Directions Introduction Many of the future research needs listed in the 1994 Agency for Health Care Policy and Research (AHCPR) clinical practice guideline Benign Prostatic
More informationDOWNLOAD OR READ : TREATMENT OF BENIGN PROSTATIC HYPERPLASIA PDF EBOOK EPUB MOBI
DOWNLOAD OR READ : TREATMENT OF BENIGN PROSTATIC HYPERPLASIA PDF EBOOK EPUB MOBI Page 1 Page 2 treatment of benign prostatic hyperplasia treatment of benign prostatic pdf treatment of benign prostatic
More informationHee Young Park, Joo Yong Lee, Sung Yul Park, Seung Wook Lee, Yong Tae Kim, Hong Yong Choi, Hong Sang Moon
www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.2.92 Voiding Dysfunction Efficacy of Alpha Blocker Treatment According to the Degree of Intravesical Prostatic Protrusion Detected by Transrectal
More informationEFFECT OF INTRAVESICAL PROSTATIC PROTRUSION (IVPP) ON LOWER URINARY TRACT FUNCTION AND MANAGEMENT
EFFECT OF INTRAVESICAL PROSTATIC PROTRUSION (IVPP) ON LOWER URINARY TRACT FUNCTION AND MANAGEMENT Rajaraman T 1, Balaji A. R 2, Vetrichandar S 3, Shekar M. G 4, Bhat K. R. S 5, Muthurathinam R 6, Ashokkumar
More informationINJINTERNATIONAL. Efficacy of Holmium Laser Enucleation of the Prostate Based on Patient Preoperative Characteristics. Original Article INTRODUCTION
Official Journal of Korean Continence Society / Korean Society of Urological Research / The Korean Children s Continence and Enuresis Society / The Korean Association of Urogenital Tract Infection and
More informationVoiding Dysfunction. Jae Hyun Bae, Sun Ouck Kim 1, Eun Sang Yoo 2, Kyung Hyun Moon 3, Yoon Soo Kyung 4, Hyung Jee Kim 4
www.kjurology.org DOI:10.4111/kju.2011.52.4.274 Voiding Dysfunction Efficacy and Safety of Low-Dose Propiverine in Patients with Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia with Storage Symptoms:
More informationChanges in Nocturia after Photoselective Vaporization of the Prostate for Patients with Benign Prostatic Hyperplasia
www.kjurology.org DOI:10.4111/kju.2010.51.8.531 Voiding Dysfunction Changes in Nocturia after Photoselective Vaporization of the Prostate for Patients with Benign Prostatic Hyperplasia Chang Ju Lee, Min
More informationEVALUATION OF THE EFFICACY OF TADALAFIL IN IMPROVING LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH SYMPTOMATIC BENIGN PROSTATIC ENLARGEMENT
Basrah Journal Of Surgery EVALUATION OF THE EFFICACY OF TADALAFIL IN IMPROVING LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH SYMPTOMATIC BENIGN PROSTATIC ENLARGEMENT MB, ChB, FIBMS, Assistant Professor
More informationEfficacy and Safety of Propiverine and Solifenacin for the Treatment of Female Patients with Overactive Bladder: A Crossover Study
LUTS () 3, 36 4 ORIGINAL ARTICLE Efficacy and Safety of Propiverine and Solifenacin for the Treatment of Female Patients with Overactive Bladder: A Crossover Study Naoki WADA, Masaki WATANABE, Masafumi
More informationOriginal Article. Annals of Rehabilitation Medicine INTRODUCTION
Original Article Ann Rehabil Med 2014;38(3):342-346 pissn: 2234-0645 eissn: 2234-0653 http://dx.doi.org/10.5535/arm.2014.38.3.342 Annals of Rehabilitation Medicine Phasic Changes in Bladder Compliance
More informationBenign Prostatic Hyperplasia (BPH):
Benign Prostatic Hyperplasia (BPH): Evidence Based Guidelines for Primary Care Providers Jeanne Martin, DNP, ANP-BC Objectives 1. Understand the pathophysiology and prevalence of BPH 2. Select the appropriate
More informationIJBCP International Journal of Basic & Clinical Pharmacology
Print ISSN: 2319-2003 Online ISSN: 2279-0780 IJBCP International Journal of Basic & Clinical Pharmacology DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20160772 Research Article Efficacy and safety of
More informationINVESTIGATION OF LOWER URINARY TRACT SYMPTOMS IN UROLOGICAL OUTPATIENTS USING ORIGINAL IPSS PLUS POST MICTURITION DRIBBLE QUESTIONNAIRE
INVESTIGATION OF LOWER URINARY TRACT SYMPTOMS IN UROLOGICAL OUTPATIENTS USING ORIGINAL IPSS PLUS POST MICTURITION DRIBBLE QUESTIONNAIRE Tadashi Hanail*, Seiji Matsumotol*, Nobutaka Shimizu, Hirotsugu Uemural
More informationThe Effect of Tamsulosin on the RestingTone and the ContractileBehaviouroftheFemaleUrethra:AFunctional Urodynamic Study in Healthy Women
European Urology European Urology 46 (24) 235 24 The Effect of Tamsulosin on the RestingTone and the ContractileBehaviouroftheFemaleUrethra:AFunctional Urodynamic Study in Healthy Women André Reitz a,*,
More informationa 1 -adrenoceptor antagonist on uro owmetric parameters in patients with benign prostatic hyperplasia
Single dose methodology to assess the in uence of an a 1 -adrenoceptor antagonist on uro owmetric parameters in patients with benign prostatic hyperplasia S. P. Curtis, 1 I. Eardley, 2 M. Boyce, 3 P. Larson,
More informationChapter 2: Methodology
Chapter 2: Methodology TABLE OF CONTENTS Introduction... 2 Study Selection and Data Abstraction... 2 Data Synthesis... 8 Guideline Development and Approvals... 9 Conflict of Interest... 10 Copyright 2010
More informationDepartment of Urology, Hirosaki University Graduate School of Medicine, Hirosaki , Japan
BioMed Research International Volume 216, Article ID 4975851, 5 pages http://dx.doi.org/1.1155/216/4975851 Clinical Study Efficacy and Safety of Silodosin and Dutasteride Combination Therapy in Acute Urinary
More informationMonth/Year of Review: May 2014 Date of Last Review: November 2012 Source Document: OSU College of Pharmacy
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights
More informationCurrent role of treatment in men with lower urinary tract symptoms combined with overactive bladder
Review Article Prostate Int 2014;2(2):43-49 P ROSTATE INTERNATIONAL Current role of treatment in men with lower urinary tract symptoms combined with overactive bladder Seung Hwan Lee, Ji Youl Lee 1 Department
More informationOveractive Bladder Syndrome
Overactive Bladder Syndrome behavioural modifications to pharmacological and surgical treatments Dr Jos Jayarajan Urologist Austin Health, Eastern Health Warringal Private, Northpark Private, Epworth Overactive
More informationLower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist
Lower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist Lower Urinary Tract Symptoms Storage Symptoms Frequency, urgency, incontinence, Nocturia Voiding Symptoms Hesitancy, poor flow, intermittency,
More informationPROSTATIC ARTERY EMBOLISATION (PAE) FOR BENIGN PROSTATIC HYPERPLASIA. A Minimally Invasive Innovative Treatment
PROSTATIC ARTERY EMBOLISATION (PAE) FOR BENIGN PROSTATIC HYPERPLASIA A Minimally Invasive Innovative Treatment What is the prostate? The prostate is an accessory organ of the male reproductive system.
More informationOverview. Urology Dine and Learn: Erectile Dysfunction & Benign Prostatic Hyperplasia. Iain McAuley September 15, 2014
Urology Dine and Learn: Erectile Dysfunction & Benign Prostatic Hyperplasia Iain McAuley September 15, 2014 Overview Review of the most recent guidelines for ED and BPH ED Guidelines CUA 2006 AUA 2011
More informationComparison of Silodosin versus Tadalafil in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia
LUTS (2017) 9, 176 186 ORIGINAL ARTICLE Comparison of Silodosin versus Tadalafil in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia Masaki YOSHIDA, 1, Hideki ORIGASA,
More informationEarly-Stage Clinical Experiences of Holmium Laser Enucleation of the Prostate (HoLEP)
JRural Med 2007 ; 2 : 93 97 Original article Early-Stage Clinical Experiences of Holmium Laser Enucleation of the Prostate (HoLEP) Shuzo Hamamoto 1,TakehikoOkamura 1,HideyukiKamisawa 1,KentaroMizuno 1,
More informationPRABHAKAR SINGH*, MANOJ INDURKAR, AMITA SINGH, PALLAVI INDURKAR
Academic Sciences International Journal of Current Pharmaceutical Research ISSN- 0975-7066 Vol 5, Issue 1, 2013 Research Article COMPARISON OF THE EFFICACY AND SAFETY OF TAMSULOSIN (0.4 V/S (and) FINASTERIDE
More informationThis Special Report supplement
...INTRODUCTION... Overactive Bladder: Defining the Disease Alan J. Wein, MD This Special Report supplement to The American Journal of Managed Care features proceedings from the workshop, Overactive Bladder:
More informationVictoria Sharp, MD, MBA, FAAFP. Clinical Professor of Urology and Family Medicine
Victoria Sharp, MD, MBA, FAAFP Clinical Professor of Urology and Family Medicine Victoria Sharp, MD, MBA, FAAFP Market Chief Medial Officer AmeriHealth Caritas Family of Companies Office phone: (515) 330-3740
More informationH6D-MC-LVHR Clinical Study Report Synopsis Page LVHR Synopsis (LY450190)
H6D-MC-LVHR Clinical Study Report Synopsis Page 1 2. LVHR Synopsis H6D-MC-LVHR Clinical Study Report Synopsis Page 2 Clinical Study Report Synopsis: Study H6D-MC-LVHR Title of Study: A Randomized, Double-Blind,
More informationDysfunctional Voiding Patients: When Do you Give Medication and Why (A Practical approach)
Dysfunctional Voiding Patients: When Do you Give Medication and Why (A Practical approach) Andrew Combs, PA-C Director, Pediatric Urodynamics Division of Pediatric Urology New York Presbyterian-Weill Cornell
More informationAN OVERVIEW OF THE MANAGEMENT OF MALE LOWER URINARY TRACT SYMPTOMS AND BENIGN PROSTATIC OBSTRUCTION
AN OVERVIEW OF THE MANAGEMENT OF MALE LOWER URINARY TRACT SYMPTOMS AND BENIGN PROSTATIC OBSTRUCTION *Richard Christian Rowan Nayar, Hashim Hashim Continence and Urodynamics Unit, Bristol Urological Institute,
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Centre for Clinical Practice Surveillance Programme
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Centre for Clinical Practice Surveillance Programme Clinical guideline CG97: The management of lower urinary tract symptoms in men Publication date May
More informationGUIDELINES ON NON-NEUROGENIC MALE LUTS INCLUDING BENIGN PROSTATIC OBSTRUCTION
GUIDELINES ON NON-NEUROGENIC MLE LUTS INCLUDING BENIGN PROSTTIC OBSTRUCTION (Text update March 2015) S. Gravas (Chair), T. Bach,. Bachmann, M. Drake, M. Gacci, C. Gratzke, S. Madersbacher, C. Mamoulakis,
More information